Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Bumrungrad: revenue beats estimates, profit falls short of expectations

Bumrungrad reported Q2 2026 total revenue of 6,278 million THB (+2.9%), which beat estimates, while earnings per share of $2.18 missed the $2.28 forecast by 4.4%. EBITDA margin was 41.4% and net profit margin 30.1%; revenue from non-Thai patients rose 7.1%, while Thai patients fell 2.2%. The board approved an increased interim dividend of 4 THB per share; management expects Q3 revenue growth of around ±3% and emphasizes internationally driven growth and upcoming expansion projects. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, BUMRUNGRAD H. -NVDR- BA 1 has already paid €0.34 in dividends. The last payout was in September.

Financials

In the last quarter, BUMRUNGRAD H. -NVDR- BA 1 had revenue of €163.77m and net profit of €49.65m

(EUR)	June 2026	YoY
Revenue	163.77m	3.95%
Gross profit	85.23m	3.12%
Net profit	49.65m	2.20%
EBITDA	67.09m	0.94%

Fundamentals

Metric	Value
Market capitalization	€3.37bn
Number of shares	794.97m
52-week high/low	€5.64 - €3.53
Dividend yield	8.91%
Dividends TTM	€0.34
Beta	0.18
P/E ratio	20.61
PEG ratio	10.16
P/B ratio	5.79
P/S ratio	6.15

Company profile

Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. The company offers diagnostic, therapeutic, and intensive care facilities in a medical center. Its outpatient clinics/centers include allergy, arrhythmia, behavioral health, breastfeeding, breast care, children, dental, diabetes, diagnostic, dialysis, digestive disease, emergency, eye, fertility and IVF, health screening, hearing and balance, heart valve, cancer, hyperbaric oxygen therapy, hypertension, joint replacement, liver, memory, men, nephrology, neuroscience, new life healthy aging, orthopedic, Parkinson's disease and movement disorders, perinatal, physical therapy and rehabilitation, plastic surgery, pulmonary, refractive surgery, robotic scoliosis and surgery, skin, sleep lab, spine, sports medicine and lifestyle, surgical, travel medicine, urology, vitalife, and women's, as well as ear, nose, and throat centers. In addition, the company is involved in the real estate assets holding activities; provision of clinical research services; distribution of pharmaceutical and medical goods in specialized stores; operation of personnel development and training center for healthcare services; and patient referral service business. It operates 580 beds and approximately 56 clinics/centers. The company was founded in 1980 and is headquartered in Bangkok, Thailand.